TRIM5 proteins inhibit the infectivity of a range of different retroviruses in a species-specific fashion (10) . The capsid protein (CA) is the viral determinant for susceptibility to this restriction (3, 17) . Rhesus macaque TRIM5␣ (TRIM5␣ rh ) restricts human immunodeficiency virus type 1 (HIV-1) replication (18) . Human TRIM5␣ (TRIM5␣ hu ) restricts "N-tropic" strains of the murine leukemia virus (N-MLV) (8, 9, 13, 21) . In owl monkey cells, HIV-1 is inhibited by TRIMCyp, the product of the TRIM5-cyclophilin (CypA) gene fusion (12, 15) . The restriction activities of TRIM5␣ rh and TRIMCyp are conferred to nonrestrictive cells upon transduction of the respective cDNAs (15, 18) . CypA modulates the restriction of HIV-1 in human and owl monkey cells in opposite ways: HIV-1 CA binding to the CypA domain of TRIMCyp (4, 5) is necessary for inhibition of HIV-1 in owl monkey cells, while "free" CypA appears to protect HIV-1 from restriction in human cells (20) .
At the C-terminus of TRIM5␣ is a variable SPRY domain that determines the species specificity of restriction (8, 9, 21) . In owl monkeys, the SPRY domain was replaced by CypA via L1-mediated retrotransposition (12, 15) . TRIM5␣ and TRIMCyp both contain a tripartite motif, composed of RING finger, B-Box, and coiled-coil domains (14, 15) , that exhibits E3 ubiquitin ligase activity (6, 18) . The coiled-coil domain promotes the formation of TRIM5 homomultimers (14) . Here we asked whether TRIM5␣ or TRIMCyp associates with TRIM5␣ hu and alters the antiviral activity of the human protein.
We transduced human rhabdomyosarcoma TE671 cells (19) with previously described LPCX vectors (15, 18) bearing cDNAs for TRIM5␣ rh , TRIMCyp, or owl monkey CypA. Cells were also transduced with a vector expressing TRIMStop, a truncated version of TRIMCyp lacking the CypA domain (15) .
Pools of transduced cells were selected in puromycin and then assessed for susceptibility to infection with HIV-1 NL-GFP (2) . For each transduced population we also tested the effect on HIV-1 infectivity of cyclosporine A (CsA), a drug that com- petes with HIV-1 CA for binding to CypA (11) . We monitored the percentage of infected (GFP-expressing) cells by fluorescence-activated cell sorting (FACS) and the synthesis of viral cDNA in the infected cells using a Southern blot designed to detect full-length, linear viral cDNA and circular viral cDNAs that form in the nucleus (1, 2, 22).
As expected, both TRIM5␣ rh and TRIMCyp inhibited HIV-1 infection of TE671 cells and inhibited HIV-1 cDNA synthesis ( Fig. 1) . TRIMCyp inhibited HIV-1 replication roughly fivefold more efficiently than TRIM5␣ rh , consistent with the higher levels of HIV-1 restriction in owl monkey cells than in macaque cells (1, 15) . CsA treatment rescued HIV-1 replication in TRIMCyp-expressing cells, as previously reported (15) . CsA also enhanced HIV-1 infection of TE671-TRIM5␣ rh , indicating that CsA partially countered HIV-1 restriction when TRIM5␣ rh was expressed in human cells. This result was expected, as CsA also counteracts the restriction to HIV-1 in Old World monkey cells (1) . At the high multiplicity of infection used here, CsA had little effect on HIV-1 infectivity; in experiments using a lower multiplicity of infection, CsA modestly decreased HIV-1 infection of control TE671 cells, as previously reported (data not shown and reference 20).
Next, we analyzed MLV replication in TE671-TRIM5␣ rh , TE671-TRIMCyp, and the control TE671-vector cells. We infected these cells with N-or B-tropic, GFP-expressing MLV vectors (2) that had identical titers in nonrestrictive Mus dunni tail fibroblasts and were normalized based on infection of these cells (19) . In control cells, B-MLV was ϳ200-fold more infectious than N-MLV ( Fig. 2A) . As 2 O 3 , a drug that counteracts restriction to N-MLV in TE671 cells (2, 9) , specifically increased N-MLV infectivity by 10-fold or more (Fig. 2) . In cells expressing TRIM5␣ rh , the N-MLV replication defect was reduced to about 20-fold (Fig. 2A) ; in cells expressing TRIMCyp, N-tropic restriction was fully abrogated (Fig. 2A) . In either case, As 2 O 3 no longer enhanced infectivity, as would be expected for cells lacking the antiviral activity targeting N-MLV.
We also performed the reciprocal experiment, transducing owl monkey OMK cells with TRIM5␣ hu and challenging them with MLV or HIV-1. TRIM5␣ hu had only a small (approximately twofold) restrictive effect on the replication of N-MLV and had no effect on B-MLV (Fig. 2B) . Restriction of HIV-1 was similar in cells expressing TRIM5␣ hu to that in the control cells (Fig. 2C) , and HIV-1 replication was rescued by CsA in both cell lines, consistent with previous reports (15, 20) . Altogether, the data in Fig. 2 suggest that TRIMCyp is dominant over TRIM5␣ hu . Since TRIMCyp (but not TRIM5␣ rh ) completely suppressed the antiviral activity of TRIM5␣ hu , we further investigated the effects of this orthologue. TRIMStop, a truncated version of TRIMCyp lacking the CypA domain (15), did not affect the capacity of TE671 cells to restrict N-MLV replication (Fig.  3A) . To determine if this was because TRIMStop was expressed at lower levels than TRIMCyp, we performed reverse transcription-PCR (RT-PCR) using conventional methods (15) . TRIMStop mRNA was expressed at least as well as TRIMCyp mRNA (Fig. 3B) ; TRIM5␣ hu was expressed at similar levels in all three cell lines (Fig. 3B) . By using Western blotting, we could not detect TRIM5 protein in the TE671 cell lines, but when 293T cells were transfected with the LPCX plasmids, TRIMStop was expressed at higher levels than TRIMCyp (Fig. 3C) .
TRIM5 homomultimerization is promoted by the coiled-coil domain (14) , which TRIMCyp also possesses. We hypothesized that the different TRIM5 orthologues heteromultimerize with each other and that TRIMStop did not interfere with TRIM5␣ hu activity because these particular proteins are incapable of interacting. We used the yeast two-hybrid system to analyze interactions between TRIMStop, TRIMCyp, TRIM5␣ hu , TRIM5␣ rh , HIV-1 Gag, and huTRIMStop, a version of TRIM5␣ hu which, like TRIMCyp, lacks the C-terminal SPRY domain. Fusions of these proteins with LexA and/or B42 were constructed, and the interactions between fusion proteins were analyzed using a previously described system (7) in which reporter gene ␤-galactosidase activity was assessed with a quantitative assay (16) . TRIMCyp interacted equally well with TRIMCyp, TRIM5␣ rh , TRIM5␣ hu , TRIMStop, huTRIMStop, and HIV-1 Gag (Fig. 4A ). Though TRIMStop was not able to interact with Gag, presumably because the CypA domain was deleted, this protein was as competent as TRIMCyp in interactions with each of the TRIM5 orthologues.
To investigate TRIM5:TRIMCyp heterodimerization in mammalian cells, we expressed TRIM5␣ hu in fusion with glutathione-S-transferase (GST) and transfected 293T cells with either GST or GST-TRIM5␣ hu . These cells were cotransfected with the LPCX plasmid constructs described above that express TRIMCyp or TRIMStop. GST pull down on glutathioneSepharose beads (Sigma) followed by Western blotting with anti-TRIM5 antibody showed that both TRIMCyp and TRIMStop associated with TRIM5␣ hu (Fig. 4B) . The blot was also probed with an anti-cyclophilin A antibody, confirming the identity of TRIMCyp (Fig. 4B) .
Finally, to examine the distribution of the tagged proteins in cells by immunofluorescence, we cloned TRIMCyp and 293T cells were transfected with GST or GST-TRIM5␣ hu (GST-T5␣) and cotransfected with LPCX (C), LPCX-TRIMCyp (TC), or LPCXTRIMStop (TS). Thirty-six hours later, the cells were lysed in 50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 1% NP40, 0.1% SDS, and GST was pulled down using glutathione-coated Sepharose beads (Pharmacia). One percent of the pre-pull-down lysate and 25% of the bound proteins were analyzed by Western blotting, using polyclonal antibodies directed against TRIM5, cyclophilin A, or GST.
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on May 1, 2014 by PENN STATE UNIV http://jvi.asm.org/ TRIMStop into p3xFLAG.CMV (SIGMA), encoding N-terminal FLAG-tagged versions of the two proteins. These constructs were each transfected into TE671 cells and detected with anti-FLAG antibody. Both TRIMCyp and TRIMStop were diffusely distributed in the cytoplasm and concentrated around the nucleus in about half of the cells. TRIM5␣ hu , expressed in fusion with GST and detected with anti-GST antibody, was cytoplasmic as well and was partly localized to cytoplasmic bodies as previously reported (14) . When TRIMCyp or TRIMStop were coexpressed in the same cells with TRIM5␣ hu , both TRIMCyp and TRIMStop showed partial localization to TRIM5␣ hu cytoplasmic bodies, suggesting that TRIMCyp and TRIMStop are both capable of heterodimerizing with TRIM5␣ hu in cells. Altogether, the results shown in Fig. 4 and 5 show that TRIM5 orthologues from different primate species heteromultimerize with each other and that failure of TRIMStop to block restriction activity of TRIM5␣ hu is not due to failure to multimerize.
In this work we show that TRIM5 proteins from different primate species interact with each other and can interfere with each other's function. The CypA domain of TRIMCyp is necessary for interference with endogenous TRIM5␣ (Fig. 3) . CsA did not affect interference by TRIMCyp (data not shown), demonstrating that CypA peptidyl-isomerase activity was not relevant for the effect. A likely possibility is that when TRIM5␣ hu /TRIMCyp heterodimers are formed, the cyclophilin A domain of TRIMCyp interferes with TRIM5␣ hu 's ability to recognize the N-MLV target. Perhaps TRIM5␣ and TRIMCyp function as multimers, with the TRIM5 C-terminus facing the viral target (consistent with the role of CypA in binding HIV-1 CA). Similar to the results reported here with different TRIM5 orthologues, the gamma isoform of macaque TRIM5 was found to inhibit TRIM5␣ rh anti-HIV restriction activity (18) .
